Rein Therapeutics Valuation
| RNTX Stock | 1.42 0.02 1.43% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Rein Therapeutics holds a recent Real Value of USD4.31 per share. The prevailing price of the company is USD1.42. Our model determines the value of Rein Therapeutics from analyzing the company fundamentals such as Price To Book of 1.05 X, shares outstanding of 21.67 M, and Return On Equity of -0.55 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Rein Therapeutics' valuation include:
Undervalued
Today
Please note that Rein Therapeutics' price fluctuation is unstable at this time. Calculation of the real value of Rein Therapeutics is based on 3 months time horizon. Increasing Rein Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Rein Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Rein Stock. However, Rein Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.42 | Real 4.31 | Target 13.0 | Hype 1.46 | Naive 1.4 |
The intrinsic value of Rein Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Rein Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Rein Therapeutics helps investors to forecast how Rein stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rein Therapeutics more accurately as focusing exclusively on Rein Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Rein Therapeutics' intrinsic value based on its ongoing forecasts of Rein Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Rein Therapeutics' closest peers.
Rein Therapeutics Cash |
|
Rein Valuation Trend
Analysing the historical paterns of Rein Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Rein Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Rein Therapeutics Total Value Analysis
Rein Therapeutics is at this time anticipated to have valuation of 35.6 M with market capitalization of 52.86 M, debt of 7.8 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Rein Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
35.6 M | 52.86 M | 7.8 M |
Rein Therapeutics Asset Utilization
One of the ways to look at asset utilization of Rein is to check how much profit was generated for every dollar of assets it reports. Rein Therapeutics holds a negative application of assets of -0.32 pct., losing USD0.003163 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Rein Therapeutics shows how discouraging it operates for each dollar spent on its assets.Rein Therapeutics Ownership Allocation
Rein Therapeutics owns a total of 21.67 Million outstanding shares. 30% of Rein Therapeutics outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Rein Therapeutics Profitability Analysis
Net Loss for the year was (62.88 M) with profit before overhead, payroll, taxes, and interest of 0.About Rein Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Rein Therapeutics. We calculate exposure to Rein Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Rein Therapeutics's related companies.Rein Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 17.9 K |
Rein Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Rein Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Rein we look at many different elements of the entity such as Rein's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Rein Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Rein Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Rein Therapeutics' worth.Additional Tools for Rein Stock Analysis
When running Rein Therapeutics' price analysis, check to measure Rein Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rein Therapeutics is operating at the current time. Most of Rein Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rein Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rein Therapeutics' price. Additionally, you may evaluate how the addition of Rein Therapeutics to your portfolios can decrease your overall portfolio volatility.